What Bain Capital Life Sciences does

Bain Capital Life Sciences is the dedicated life sciences investment franchise of Bain Capital, LP, founded in 2016 to build on Bain Capital's four decades of healthcare and life sciences investing across private equity, public equity, credit, venture capital, and real estate. The firm invests across biopharmaceutical, medical device, diagnostic, and life science tool companies globally, managing an estimated $7B+ in assets under management as of December 31, 2025 across 63+ portfolio companies and 18+ medicines or technologies approved or launched. Its strategy is organized around four explicit opportunity types: Inflection Capital (critical stages of development), Growth Capital (commercialization and geographic expansion), Fallen Angels (companies at a crossroads), and Transformation at Scale (NewCo formations and large-scale restructurings). The firm operates dedicated offices in Boston, New York, Melbourne, and Shanghai, with additional team presence in London and Hong Kong via the parent Bain Capital platform.

The team is distinguished by senior scientific and operating expertise — Partners and senior staff with MD/PhD credentials from Biogen, Editas Medicine, Pfizer, Millennium Management, Avidity Partners, KKR, Longitude Capital, McKinsey, J.P. Morgan healthcare banking, and Genentech, supported by functional leaders in finance, legal, HR, and IT. The portfolio spans clinical-stage through commercial-stage therapeutics across oncology, neuroscience, immunology, cardiometabolic, ophthalmology, and rare disease (e.g., Beeline Medicines, Cabaletta Bio, Cerevel Therapeutics, Kailera, SpringWorks Therapeutics), alongside medical devices (HeartFlow, Imperative Care, JenaValve, CereVasc, Apreo, Gynesonics, Kestra), diagnostics (Freenome, Natera), and life science tools (Rapid Micro Biosystems, FIS, Nimbus, Synthekine).

As a private investment firm, BCLS generates returns through capital appreciation across fund vehicles (including BCLS Fund III Investments, LP, referenced in HeartFlow filings). Deal types span primary equity rounds, PIPE/registered direct offerings, convertible note financings, secondary share purchases, and bespoke NewCo formations with major pharma counterparties such as Bristol Myers Squibb (Beeline Medicines, $300M Series A led) and Jiangsu Hengrui Pharmaceuticals (Kailera Therapeutics). Recent realized exits include Affinivax and Aiolos Bio (acquired by GSK), ViaCyte (acquired by Vertex), Constellation Pharmaceuticals (acquired by MorphoSys), and Kailera's $719M Nasdaq IPO in April 2026.

Name

Bain Capital Life Sciences

Legal name

Bain Capital Life Sciences (a business of Bain Capital, LP)

Website

https://baincapitallifesciences.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Bain Capital Life Sciences is the dedicated life sciences investment franchise of Bain Capital, deploying $7B+ AUM across biopharmaceutical, medical device, diagnostic, and life science tool companies globally via four investment strategies: Inflection Capital, Growth Capital, Fallen Angels, and Transformation at Scale.

Ownership category

akta.pro rank

Product category

Life Sciences Private Equity & Venture Capital

NAICS

Portfolio Management and Investment Advice (52394), Other Financial Investment Activities (5239), Other Financial Vehicles (525990)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Life sciences private equity
• Healthcare venture capital
• Biopharmaceutical investment
• Medical device investing
• Biotech growth capital

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Investment-driven returns (capital appreciation, exits, and carried interest): As a private investment firm, BCLS generates returns through long-duration investments in life sciences companies across inflection, growth, fallen-angel, and transformation-at-scale theses. Returns are realized via IPOs (e.g., Kailera), M&A exits (e.g., Affinivax to GSK, Aiolos Bio to GSK, ViaCyte to Vertex, Revolution Medicines acquisition of EQRx), recapitalizations, and secondary sales. Specific management fee/carry economics are not publicly disclosed in the source material.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels5 records

Core offering

Bain Capital Life Sciences deploys institutional capital into life sciences companies across biopharmaceuticals, medical devices, diagnostics, and life science tools. The firm pursues four investment theses — Inflection Capital, Growth Capital, Fallen Angels, and Transformation at Scale — through primary equity rounds, PIPEs, convertibles, secondaries, and NewCo formations, generating returns via IPOs, M&A exits, and recapitalizations.

Product overview

Bain Capital Life Sciences is a single, unified life sciences-focused investment platform (not a software product suite) founded in 2016 and built on Bain Capital's four decades of healthcare investing. The firm manages $7B+ in assets and pursues investments across biopharmaceutical, medical device, diagnostic, and life science tool companies globally. Its offering is organized around four investment strategies: Inflection Capital (e.g., Beeline Medicines, Cerevasc), Growth Capital (e.g., Nuvalent, Angitia), Fallen Angels (e.g., Olema Oncology, Dicerna Pharmaceuticals), and Transformation at Scale (e.g., the Bristol Myers Squibb NewCo/Beeline Medicines creation, Tanabe Pharma acquisition). The portfolio comprises 63+ companies spanning Abcuro (immunotherapies for autoimmune disease), Cabaletta Bio (engineered T cell therapies), CereVasc (eShunt neuro device), HeartFlow (AI-powered FFRCT coronary analysis), Freenome (multiomics early cancer detection), SpringWorks Therapeutics (OGSIVEO/nirogacestat for desmoid tumors), Syremis (muscarinic/NMDA mental health therapies), Kailera (GLP-1/GIP obesity drugs), Solid Biosciences (gene therapy for Duchenne), and many others. These named portfolio companies represent Bain Capital Life Sciences' discrete investment "products" — i.e., the distinct operating companies in which the firm holds positions across various therapeutic areas (oncology, neuroscience, immunology, cardiometabolic, ophthalmology, rare disease, etc.) and stages (clinical, commercial, fallen-angel, and NewCo formation).

Differentiator

Problem solved

Functional benefit

Products and services

• Inflection Capital Strategy Bain Capital Life Sciences' investment strategy focused on companies at critical stages of development, providing clinical-stage inflection capital to advance programs through key value-creating milestones such as pivotal trials and regulatory inflection points.
• Growth Capital Strategy Bain Capital Life Sciences' investment strategy providing growth-stage capital to support companies in accelerating commercialization and geographic expansion, including US market entry and international scaling.
• Fallen Angels Strategy Bain Capital Life Sciences' investment strategy partnering with companies at a crossroads — typically underperforming public biotechs or companies facing restructurings — to create value through operational and strategic repositioning.
• Transformation at Scale Strategy Bain Capital Life Sciences' investment strategy focused on creating, building, and restructuring companies at scale, exemplified by NewCo formations with major pharma counterparties (e.g., Beeline Medicines with Bristol Myers Squibb, Kailera Therapeutics with Hengrui Pharma) and large public-to-private transactions (e.g., the $3.3B acquisition of Tanabe Pharma).

Quantifiable outcome

• $7B+ AUM as of Dec 31, 2025
• +4 more outcomes

Named customers14 records

Segments6 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered flagship.

• Bain Capital Private EquityflagshipStrategic or Co-development Partner · 14 October 2025Bain Capital Private Equity (the sister firm to Bain Capital Life Sciences within Bain Capital) co-led Kailera Therapeutics' $600 million Series B financing alongside new and existing investors including Adage Capital Management and Bain Capital Life Sciences. Bain Capital as a firm invests across Life Sciences, Private Equity, Credit, Ventures, Real Estate, Special Situations, and Tech Opportunities, drawing on >40 years of healthcare investing experience globally.
• Bristol Myers SquibbflagshipStrategic or Co-development Partner · 28 July 2025BMS and Bain Capital jointly created Beeline Medicines as a NewCo with five immunology assets in-licensed from BMS (afimetoran, BMS-986326, BMS-986322/lomedeucitinib, BMS-986481, BMS-986498) targeting autoimmune and inflammatory diseases. BMS retained a ~20% equity stake and is entitled to royalties and milestones; BMS Chief Research Officer Robert Plenge joined the NewCo Board. Bain Capital led a $300 million financing commitment, with Canada Pension Plan Investment Board also participating. Daniel S. Lynch serves as Executive Chairman; Nicholas Downing, Adam Koppel, and Andrew Kaplan of Bain Capital joined the Board.
• Jiangsu Hengrui PharmaceuticalsflagshipOEM/ Whitelabel/ Licensing Partner · 1 January 2024BCLS-led consortium acquired foreign rights to Hengrui Pharma's weight-loss drug portfolio in 2024 to form Kailera Therapeutics; Hengrui's HRS9531 (an injectable GLP-1/GIP dual agonist with positive Phase 2 obesity and type 2 diabetes results in China) became Kailera's lead asset KAI-9531. Kailera subsequently raised a $600M Series B (Oct 2025) and $719M Nasdaq IPO (April 2026).

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• RA Capital Management: Healthcare-focused crossover and life sciences investor that co-invests with BCLS across multiple rounds (Solid Biosciences $240M, Freenome PIPE, AavantiBio Series A). Both firms deploy capital across private and public life sciences with similar scale and stage mix.
• Perceptive Advisors: Life sciences-focused investment manager that co-led the Imperative Care $100M convertible and anchored the Solid Biosciences $240M private placement alongside BCLS. Comparable crossover-style strategy spanning inflection, growth, and public/structured life sciences.
• Blackstone Life Sciences: The life sciences private equity arm of Blackstone, the closest direct competitor to BCLS. Both firms invest at scale across biopharma, devices, and tools, deploy multi-hundred-million-dollar checks, and partner with strategics on NewCo creations and royalty/financing deals.
• OrbiMed: One of the largest dedicated healthcare investment firms globally, spanning venture, growth, and public equity across biopharma, medical devices, and diagnostics. Direct competitor for healthcare-focused PE capital with comparable stage and check-size range.
• Patient Square Capital: Healthcare-focused private equity firm investing across biopharma and medical products, comparable to BCLS in its stage-agnostic approach and willingness to do control buyouts and growth capital. Directly comparable on thesis breadth and check size.

Broad incumbents

• KKR Healthcare Strategic Growth: KKR's dedicated healthcare growth equity strategy. Allyson Rinderle (BCLS MD) previously was a Principal at KKR Healthcare Growth Equity, illustrating direct talent overlap and competitive overlap for late-stage healthcare deals.
• TPG Life Sciences Innovations: TPG's life sciences franchise investing across biopharma and medtech. Part of a broader private equity platform similar in mandate to BCLS within Bain Capital, competing for similar scale transactions.
• Carlyle Global Healthcare: Healthcare-focused private equity team within Carlyle, investing across pharma services, biopharma, devices, and healthcare IT. Comparable large-cap healthcare PE platform with similar stage mix.

Emerging players

• ARCH Venture Partners: One of the largest and most established early-stage life sciences venture firms. Competes with BCLS at the clinical-inflection and company-formation stages (NewCos) but is focused earlier in the lifecycle and does not have BCLS's growth/fallen-angel toolbox.
• Atlas Venture: Early-stage life sciences venture firm that frequently co-invests with BCLS at the Series A stage. Overlaps with BCLS's Inflection Capital and Transformation at Scale theses but is exclusively pre-clinical and clinical-stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/BainCapital
• YouTubeyoutube.com/@BainCapital
• Facebookfacebook.com/BainCapital
• LinkedInlinkedin.com/company/bain-capital
• Instagraminstagram.com/baincapital

Revenue estimate

Valuation estimate

Number of profiles

Profiles30 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments127 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bain Capital Life Sciences